Skip to main content

Sequenom Posts Slight Rise in Q4 Revenues, Decrease in Net Losses

NEW YORK, Feb. 10 (GenomeWeb News) - Sequenom today reported an uptick in revenues for the fourth quarter ended Dec. 31, 2003, accompanied by narrowed losses and decreased R&D spending.

Sequenom's consolidated revenues for the quarter were $8.0 million, up slightly from $7.7 million in the year-ago period. The company's Genetic Systems business unit posted revenues of $7.7 million for the quarter, up from $7.2 million for the fourth quarter of 2002. Revenues for the company's pharmaceuticals business unit were down year-over-year, to $300,000 from $500,000 in the fourth quarter of 2002. Sequenom said these revenues resulted primarily from genetic services.

The company reported a 78 percent decrease in its net loss for the quarter, to $10.0 million, or $0.25 per share, from $45.8 million, or $1.16 per share, in the fourth quarter of 2002.

Sequenom's R&D expenses were $7.0 million for the fourth quarter, down from $8.0 million in the prior year.

On Dec. 31, 2003, Sequenom held cash, cash equivalents, short-term investments, and restricted cash totaling $67.5 million, compared to $102.6 million at the end of 2002.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.